B Burtness

Summary

Affiliation: Fox Chase Cancer Center
Country: USA

Publications

  1. doi request reprint Novel targets in HPV-negative head and neck cancer: overcoming resistance to EGFR inhibition
    Barbara Burtness
    Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    Lancet Oncol 14:e302-9. 2013
  2. ncbi request reprint Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study
    Barbara Burtness
    Department of Internal Medicine, Yale University School of Medicine, New Haven, CT, USA
    J Clin Oncol 23:8646-54. 2005
  3. ncbi request reprint Her signaling in pancreatic cancer
    Barbara Burtness
    Fox Chase Cancer Center, Department of Medical Oncology, Division of Medical Science, Philadelphia, PA 19111, USA
    Expert Opin Biol Ther 7:823-9. 2007
  4. ncbi request reprint Clinical use of monoclonal antibodies to the epidermal growth factor receptor in colorectal cancer
    Barbara Burtness
    Fox Chase Cancer Center Philadelphia, Pennsylvania 19111, USA
    Oncology (Williston Park) 21:964-70; discussion 970, 974, 976-7. 2007
  5. ncbi request reprint Phase II trial of weekly docetaxel/irinotecan combination in advanced pancreatic cancer
    Barbara Burtness
    Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    Cancer J 13:257-62. 2007
  6. doi request reprint A randomized phase II study of ixabepilone (BMS-247550) given daily x 5 days every 3 weeks or weekly in patients with metastatic or recurrent squamous cell cancer of the head and neck: an Eastern Cooperative Oncology Group study
    B A Burtness
    Department of Medical Oncology, Division of Medical Sciences, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA 19111, USA
    Ann Oncol 19:977-83. 2008
  7. pmc Phase II trial of docetaxel-irinotecan combination in advanced esophageal cancer
    B Burtness
    Division of Medical Sciences, Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    Ann Oncol 20:1242-8. 2009
  8. ncbi request reprint The role of cetuximab in the treatment of squamous cell cancer of the head and neck
    Barbara Burtness
    Fox Chase Cancer Center, 333 Cottman Ave, Philadelphia, PA 19111, USA
    Expert Opin Biol Ther 5:1085-93. 2005
  9. doi request reprint Defining venous involvement in borderline resectable pancreatic cancer
    Yun Shin Chun
    Department of Surgical Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA
    Ann Surg Oncol 17:2832-8. 2010
  10. ncbi request reprint NCCN Task Force Report: Management of dermatologic and other toxicities associated with EGFR inhibition in patients with cancer
    Barbara Burtness
    Fox Chase Cancer Center, USA
    J Natl Compr Canc Netw 7:S5-21; quiz S22-4. 2009

Collaborators

Detail Information

Publications28

  1. doi request reprint Novel targets in HPV-negative head and neck cancer: overcoming resistance to EGFR inhibition
    Barbara Burtness
    Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    Lancet Oncol 14:e302-9. 2013
    ....
  2. ncbi request reprint Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study
    Barbara Burtness
    Department of Internal Medicine, Yale University School of Medicine, New Haven, CT, USA
    J Clin Oncol 23:8646-54. 2005
    ..These cancers are rich in epidermal growth factor receptor (EGFR). We wished to determine whether the addition of cetuximab, which inhibits activation of EGFR, would improve PFS...
  3. ncbi request reprint Her signaling in pancreatic cancer
    Barbara Burtness
    Fox Chase Cancer Center, Department of Medical Oncology, Division of Medical Science, Philadelphia, PA 19111, USA
    Expert Opin Biol Ther 7:823-9. 2007
    ..Improved patient selection and rational combination of targeted therapies will be necessary to optimize the management of patients with this tragic disease...
  4. ncbi request reprint Clinical use of monoclonal antibodies to the epidermal growth factor receptor in colorectal cancer
    Barbara Burtness
    Fox Chase Cancer Center Philadelphia, Pennsylvania 19111, USA
    Oncology (Williston Park) 21:964-70; discussion 970, 974, 976-7. 2007
    ....
  5. ncbi request reprint Phase II trial of weekly docetaxel/irinotecan combination in advanced pancreatic cancer
    Barbara Burtness
    Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    Cancer J 13:257-62. 2007
    ..We have previously demonstrated the safety of docetaxel 35 mg/m(2) and irinotecan 50 mg/m(2) given on days 1, 8, 15, and 21 of a 35-day schedule...
  6. doi request reprint A randomized phase II study of ixabepilone (BMS-247550) given daily x 5 days every 3 weeks or weekly in patients with metastatic or recurrent squamous cell cancer of the head and neck: an Eastern Cooperative Oncology Group study
    B A Burtness
    Department of Medical Oncology, Division of Medical Sciences, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA 19111, USA
    Ann Oncol 19:977-83. 2008
    ..A high incidence of motor and sensory grade 3 neuropathy resulted at this dose and schedule. Further development of ixabepilone in previously treated head and neck cancer is not warranted on the basis of these data...
  7. pmc Phase II trial of docetaxel-irinotecan combination in advanced esophageal cancer
    B Burtness
    Division of Medical Sciences, Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    Ann Oncol 20:1242-8. 2009
    ..We previously demonstrated the safety of docetaxel 35 mg/m2 and irinotecan 50 mg/m2 given on days 1 and 8 of a 21-day schedule...
  8. ncbi request reprint The role of cetuximab in the treatment of squamous cell cancer of the head and neck
    Barbara Burtness
    Fox Chase Cancer Center, 333 Cottman Ave, Philadelphia, PA 19111, USA
    Expert Opin Biol Ther 5:1085-93. 2005
    ..Thus, cetuximab is biologically active across a range of clinical scenarios in squamous cell carcinoma of the head and neck. Ongoing studies will be important in establishing its role in the routine management of head and neck cancer...
  9. doi request reprint Defining venous involvement in borderline resectable pancreatic cancer
    Yun Shin Chun
    Department of Surgical Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA
    Ann Surg Oncol 17:2832-8. 2010
    ..There is no consensus about what degree of venous impingement constitutes borderline resectability...
  10. ncbi request reprint NCCN Task Force Report: Management of dermatologic and other toxicities associated with EGFR inhibition in patients with cancer
    Barbara Burtness
    Fox Chase Cancer Center, USA
    J Natl Compr Canc Netw 7:S5-21; quiz S22-4. 2009
    ....
  11. ncbi request reprint Phase I dose escalation trial of weekly docetaxel plus irinotecan in patients with advanced cancer
    Eric Bleickardt
    Yale University School of Medicine, New Haven, Connecticut 06520, USA
    Cancer Biol Ther 1:646-51. 2002
    ..Phase II trials of this regimen are ongoing or planned in lung, head and neck, stomach, esophageal, and pancreatic cancers...
  12. ncbi request reprint Antibody therapy for early-stage breast cancer: trastuzumab adjuvant and neoadjuvant trials
    Ranee Mehra
    Fox Chase Cancer Center, Division of Medical Sciences, Department of Medical Oncology, 333 Cottman Ave, Philadelphia, PA 19111, USA
    Expert Opin Biol Ther 6:951-62. 2006
    ..In a combined analysis of two such studies, overall survival was improved (hazard ratio for death 0.67, p = 0.015). The agent has associated cardiotoxicity. Trastuzumab is a highly active agent in Her2-overexpressing breast cancer...
  13. ncbi request reprint Remarkably high frequency of EGFR expression in breast carcinomas with squamous differentiation
    V Bossuyt
    Department of Pathology, Yale University School of Medicine, New Haven, CT 06510, USA
    Int J Surg Pathol 13:319-27. 2005
    ..Breast carcinomas with squamous differentiation are a distinct subgroup of breast tumors with a very high frequency of EGFR positivity. Breast carcinomas of this type would be ideal candidates for a trial with EGFR inhibitors...
  14. ncbi request reprint Phosphorylation of Akt (Ser473) predicts poor clinical outcome in oropharyngeal squamous cell cancer
    Ziwei Yu
    Department of Surgery, Yale Cancer Center, P O Box 208032, New Haven, CT 06520, USA
    Cancer Epidemiol Biomarkers Prev 16:553-8. 2007
    ..We sought to determine the prognostic significance of Akt activation in a cohort of patients with OSCC as well as the association between phosphorylated (activated) Akt and PTEN levels...
  15. ncbi request reprint Images in clinical medicine. Cetuximab-associated acneiform eruption
    Jeremy E Moss
    Yale University, New Haven, CT 06520 8032, USA
    N Engl J Med 353:e17. 2005
  16. doi request reprint Molecular profile of head and neck squamous cell carcinomas bearing p16 high phenotype
    T Rampias
    Department of Surgery Otolaryngology, Yale University School of Medicine, New Haven, CT, USA
    Ann Oncol 24:2124-31. 2013
    ..In addition, our aim was to explore how expression of biomarkers is modulated after E6/E7 repression in HPV16⁺ oropharyngeal cancer cells...
  17. pmc Nuclear localization of signal transducer and activator of transcription 3 in head and neck squamous cell carcinoma is associated with a better prognosis
    Eirini Pectasides
    Department of Internal Medicine Medical Oncology, Yale University School of Medicine, New Haven, Connecticut, USA
    Clin Cancer Res 16:2427-34. 2010
    ..To further elucidate the prognostic role of STAT3 in HNSCC, the expression pattern of STAT3 was correlated with outcome in two independent data sets...
  18. ncbi request reprint Doxorubicin cardiotoxicity: prevention of congestive heart failure with serial cardiac function monitoring with equilibrium radionuclide angiocardiography in the current era
    Isao Mitani
    Department of Medicine, Yale University School of Medicine, New Haven, Conn, USA
    J Nucl Cardiol 10:132-9. 2003
    ..Serial left ventricular ejection fraction (LVEF) monitoring during doxorubicin therapy for preventing CHF was proposed over 20 years ago. The current utility and cost-effectiveness of this approach in the present era are not known...
  19. ncbi request reprint Oropharyngeal cancer
    Amanda Psyrri
    Head and Neck Oncology Unit, Yale University School of Medicine, New Haven, CT 06520, USA
    Clin Adv Hematol Oncol 6:604-12. 2008
    ....
  20. ncbi request reprint Correlates and determinants of nuclear epidermal growth factor receptor content in an oropharyngeal cancer tissue microarray
    Amanda Psyrri
    Department of Medical Oncology, Yale University School of Medicine, New Haven, Connecticut, USA
    Cancer Epidemiol Biomarkers Prev 17:1486-92. 2008
    ..Nuclear EGFR levels were inversely correlated with survival and response to radiotherapy. Here, we sought to identify the determinants and correlates of nuclear EGFR content...
  21. ncbi request reprint Epidermal growth factor receptor, p53 mutation, and pathological response predict survival in patients with locally advanced esophageal cancer treated with preoperative chemoradiotherapy
    Michael K Gibson
    Division of Medical Oncology, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland 21231, USA
    Clin Cancer Res 9:6461-8. 2003
    ..This study evaluates the role of clinical and cellular markers in predicting CR and OS in patients with esophageal cancer...
  22. ncbi request reprint Sequential high-dose alkylating therapy and stem cell support for high-risk stage III breast cancer
    Josette Bou-Khalil
    Bridgeport Hospital, Bridgeport, Connecticut, USA
    Breast J 9:472-7. 2003
    ..5 months. Time to relapse in this small series is only modestly improved over historical experience with standard-dose adjuvant chemotherapy. Alternative strategies for treating locally advanced breast cancer should be pursued...
  23. ncbi request reprint Mature survival results with preoperative cisplatin, protracted infusion 5-fluorouracil, and 44-Gy radiotherapy for esophageal cancer
    Lawrence Kleinberg
    Sidney Kimmel Oncology Center at Johns Hopkins, Baltimore, MD 21231, USA
    Int J Radiat Oncol Biol Phys 56:328-34. 2003
    ..To assess the long-term survival results after cisplatin, protracted infusion 5-fluorouracil, and concurrent radiotherapy (RT) followed by surgical resection of esophageal cancer...
  24. ncbi request reprint Sequence of radiotherapy with tamoxifen in conservatively managed breast cancer does not affect local relapse rates
    Peter H Ahn
    Albert Einstein College of Medicine of Yeshiva University, Bronx, NY, USA
    J Clin Oncol 23:17-23. 2005
    ..To evaluate whether the sequencing of tamoxifen (TAM) relative to radiation (RT) affects outcome in breast cancer patients treated with conservative surgery (CS) plus RT (lumpectomy with RT)...
  25. ncbi request reprint Cetuximab: an epidermal growth factor receptor chemeric human-murine monoclonal antibody
    Joanne Harding
    Medical Information Department, Prous Science, Barcelona, Spain
    Drugs Today (Barc) 41:107-27. 2005
    ..Thus, cetuximab is emerging as a very promising new therapy to be used in conjunction with existing therapies for the treatment of a spectrum of solid tumors...
  26. ncbi request reprint Cetuximab and cisplatin for chemotherapy-refractory squamous cell cancer of the head and neck
    Barbara Burtness
    J Clin Oncol 23:5440-2. 2005
  27. ncbi request reprint Oxaliplatin induces a delayed immune-mediated hemolytic anemia: a case report and review of the literature
    Vanita Noronha
    Mid Valley Oncology Hematology, P C, 407 Gidney Avenue, Newburgh, NY 12550, USA
    Clin Colorectal Cancer 5:283-6. 2005
    ..We review the literature on oxaliplatin-induced immune-mediated hemolysis, including its mechanism, presenting symptoms, laboratory features, management, and implications for future therapy...